title: Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia").
abstract: Among 16 patients with Down's syndrome (DS) and acute leukemia admitted to our department during a ten year period, 6 were diagnosed as acute megakaryoblastic leukemia (AMkL). The diagnosis was based on clinical and hematologic criteria, confirmed in three patients with the use of monoclonal antibodies (MoAb) specific for megakaryocytic antigens. In these three, and in a fourth patient, the leukemic blasts were positive for other myeloid, lymphoid and erythroid markers in MoAb testing. We suggest that AMkL in DS is a mixed lineage leukemia with blasts presenting a variety of cell surface antigens, indicating origin from an early progenitor cell with the capability of megakaryocytic differentiation. Of the 6 patients with AMkL, 4 treated with standard AML protocols are in complete continuing remission (CCR) with observation periods from 57+ to 148+ months.
authors: Department of Pediatrics, National Hospital, University of Oslo, Norway.
authors: S H
authors: SH
authors: Slørdahl
authors: E B
authors: EB
authors: Smeland
authors: H
authors: H
authors: Holte
authors: M
authors: M
authors: Grønn
authors: S O
authors: SO
authors: Lie
authors: M
authors: M
authors: Seip
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D014408:Biomarkers, Tumor; D003561:Cytarabine / Q000627:therapeutic use; D004314:Down Syndrome / Q000150:complications*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008856:Microscopy, Fluorescence; D014411:Neoplastic Stem Cells / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D003561:Cytarabine; D004317:Doxorubicin